Tuesday November 20, 2018 15:07

Heathcare Press Release : 19 Sep 2011

ONGLYZA(TM) (saxagliptin) When Added to Insulin in Adults with Type 2 Diabetes Maintained Heathcare—19 Sep 11

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA(TM) (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin)